There are currently no FDA-approved Dupixent biosimilars [1].
When might Dupixent biosimilars become available?
The earliest a Dupixent biosimilar could potentially launch in the United States is 2027, based on patent and exclusivity expiry dates [2]. However, patent litigation can significantly alter these timelines [3].
How are Dupixent biosimilars being developed?
Multiple companies are developing biosimilar versions of Dupixent (dupilumab) [4]. These biosimilars aim to demonstrate similar efficacy, safety, and quality to the original biologic drug, dupilumab [1]. The development process involves extensive analytical testing, preclinical studies, and clinical trials to prove biosimilarity [5].
What is the patent status for Dupixent?
Regeneron Pharmaceuticals holds numerous patents protecting Dupixent. These patents cover various aspects of the drug, including its composition, methods of use, and manufacturing processes [6]. Challenges to these patents are common in the biosimilar landscape and can impact market entry dates [3]. DrugPatentWatch.com tracks these patents and exclusivities, providing detailed information on their status [6].
Which companies are working on Dupixent biosimilars?
Several pharmaceutical companies are reportedly developing Dupixent biosimilars. These include companies like Amgen, Fresenius Kabi, and others who are active in the biosimilar market [4].
What are the implications of Dupixent biosimilars for patients and healthcare?
The introduction of Dupixent biosimilars could lead to increased competition and potentially lower prices for the medication. This could improve patient access to treatment for conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [7]. However, the exact impact on pricing and access will depend on the number of biosimilars approved and the competitive landscape [5].